RTW Biotech OpportunitiesLSE:RTW -0.42%42 Return-on-Tangible-Equity is 78.85% as of Dec. 2025, which is 221% above its 10-year median of 24.53. GuruFocus rates LSE:RTW with a GF Score™ of 42/100. The stock has 2 warning signs investors should review. Among 1,589 Asset Management companies, RTW Biotech Opportunities ranks better than 89.3% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. RTW Biotech Opportunities's annualized net income for the quarter that ended in Dec. 2025 was $571.9 Mil. RTW Biotech Opportunities's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $725.2 Mil. Therefore, RTW Biotech Opportunities's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 78.85%.
The historical rank and industry rank for RTW Biotech Opportunities's Return-on-Tangible-Equity or its related term are showing as below:
LSE:RTW'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -16.09 Med: 24.53 Max: 51.25
Current: 35.31
During the past 8 years, RTW Biotech Opportunities's highest Return-on-Tangible-Equity was 51.25%. The lowest was -16.09%. And the median was 24.53%.
LSE:RTW's Return-on-Tangible-Equity is ranked better than 89.3% of 1589
companies
in the Asset Management industry
Industry Median: 7.21
vs LSE:RTW: 35.31
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
RTW Biotech Opportunities Return-on-Tangible-Equity Related Terms
RTW Biotech Opportunities Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for RTW Biotech Opportunities's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:RTW vs BLK, BX, KKR: Return-on-Tangible-Equity Comparison
For the Asset Management subindustry, RTW Biotech Opportunities's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities Return-on-Tangible-Equity vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 78.85% mean?
RTW Biotech Opportunities (LSE:RTW) has a Return-on-Tangible-Equity of 78.85% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on RTW Biotech Opportunities and its competitors. This is 221% above median its historical median of 24.53. According to the industry distribution chart, RTW Biotech Opportunities ranks #170 out of 1589 companies in the Asset Management industry, placing it in the top 10.7%.
Is RTW Biotech Opportunities' Return-on-Tangible-Equity too high?
RTW Biotech Opportunities' current Return-on-Tangible-Equity of 78.85% is 221% above median its 10-year median of 24.53. The Asset Management industry median Return-on-Tangible-Equity is 7.21. RTW Biotech Opportunities' value of 78.85% is 993.6% above this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #170 out of 1589 companies in the Asset Management industry, which is in the top quartile — a strong position relative to peers. Overall, RTW Biotech Opportunities has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Return-on-Tangible-Equity compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #170 out of 1589 companies for Return-on-Tangible-Equity. This places RTW Biotech Opportunities in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.21. RTW Biotech Opportunities' value of 78.85% is 993.6% above this benchmark. While the company's 10-year median is 24.53 vs. the industry median of 7.21, RTW Biotech Opportunities has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for an Asset Management company?
The median Return-on-Tangible-Equity among Asset Management companies is 7.21, based on 1,589 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current Return-on-Tangible-Equity of 78.85% is 993.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median Return-on-Tangible-Equity is 7.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current Return-on-Tangible-Equity is 78.85%, which is 221% above median its own 10-year median of 24.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Return-on-Tangible-Equity of 78.85%. The current Return-on-Tangible-Equity is 78.85%, which is 221% above median its 10-year median of 24.53 and 993.6% above the Asset Management industry median of 7.21. RTW Biotech Opportunities' overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Return-on-Tangible-Equity is 78.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
42GF Score
Get the complete analysis for LSE:RTW
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
